Dimethylamine

Dimethylamine

SCHEMBL2579562

CNC.O=[N+]([O-])c1ccc(-c2c[nH]nc2O)cc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.44
DYRK1B Q9Y463 1/20 0.44
GYS1 P13807 1/20 0.43
ALDH1A1 P00352 3/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
XDH P47989 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 4/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
NOTUM Q6P988 1/20 0.39
SLC6A3 Q01959 2/20 0.39
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1385051 0.94 GYS1 (0.47) DYRK1ADYRK1BGYS1ALDH1A1XDH
Dimethylamine SCHEMBL2575644 0.83 IDO1 (0.46) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL1386169 0.77 IDO1 (0.50) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL24209378 0.76 MEN1 (0.54) GYS1ALDH1A1XDHMEN1KMT2A
SCHEMBL18740712 0.75 XDH (0.45) DYRK1ADYRK1BGYS1ALDH1A1XDH
SCHEMBL11763106 0.71 AR (0.54) MEN1KMT2AMAPTGAAHTT
P-Nitrophenol SCHEMBL27528063 0.69 ALDH1A1 (0.59) ALDH1A1RECQLHSD17B10MEN1KMT2A
SCHEMBL2581914 0.68 BACE1 (0.44) DYRK1BALDH1A1HSD17B10LMNA
SCHEMBL13712890 0.68 SLC6A3 (0.53) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL4317166 0.66 ABCC8 (0.46) ALDH1A1XDHMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2009-07-02 US claimed
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2005-07-28 US claimed
US-8048893-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA SA (FR) 2011-11-01 US disclosed
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2009-07-02 US disclosed
US-7524838-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2009-04-28 US disclosed
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM C1R, CBR3, C3AR1 DYRK1A 324/4885DYRK1B 868/4885GYS1 3600/4885
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them C1R, CBR3, C3AR1 DYRK1A 353/4885DYRK1B 920/4885GYS1 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.